Clinical Outcomes of Patients with Rare and Heavily Pretreated Solid Tumors Treated according to the Results of Tumor Molecular Profiling

BioMed Research International

Volumn 2016, Issue , 2016, Pages

  Dean, Andrew ^a   Byrne, Aisling ^a   Marinova, Mira ^a   Hayden, Ingrid ^a  

^a ST JOHN OF GOD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; CISPLATIN; EPIRUBICIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; PACLITAXEL; SUNITINIB; TRASTUZUMAB; CAMPTOTHECIN; TUMOR MARKER; TUMOR PROTEIN;

ADRENAL CORTEX CARCINOMA; ARTICLE; BIOLOGICAL THERAPY; BREAST METASTASIS; CANCER CHEMOTHERAPY; CLINICAL DECISION MAKING; FEMALE; HEALTH CARE QUALITY; HEAVILY PRETREATED SOLID TUMOR; HUMAN; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL PROCEDURES; MOLECULAR PROFILING; OUTCOME ASSESSMENT; PANCREAS ADENOCARCINOMA; POST TREATMENT SURVIVAL; PROGRESSION FREE SURVIVAL; RARE DISEASE; SMALL CELL LUNG CANCER; SOLID TUMOR; SYMPTOM; THYROID CANCER; UTERINE CERVIX CANCER; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; DISEASE FREE SURVIVAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; MOLECULAR PATHOLOGY; NEOPLASMS; PATHOLOGY;

BIOMARKERS, TUMOR; CAMPTOTHECIN; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASM PROTEINS; NEOPLASMS; PATHOLOGY, MOLECULAR;

EID: 84982867248     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2016/4627214     Document Type: Article

References (26)

1. N. B. Leighl, P. N. Butow, and M. H. N. Tattersall, "Treatment decision aids in advanced cancer: when the goal is not cure and the answer is not clear, " Journal of Clinical Oncology, vol. 22, no. 9, pp. 1759-1762, 2004.
2. D. Olmos, R. P. A'Hern, S. Marsoni et al., "Patient selection for oncology phase I trials: Amulti-institutional study of prognostic factors, " Journal of Clinical Oncology, vol. 30, no. 9, pp. 996-1004, 2012.
3. N. Murugaesu, S. K. Chew, and C. Swanton, "Adapting clinical paradigms to the challenges of cancer clonal evolution, " The American Journal of Pathology, vol. 182, no. 6, pp. 1962-1971, 2013.
4. J. Stenvang, I. Kümler, S. B. Nygard et al., "Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: A novel strategy in drug development, " Frontiers in Oncology, vol. 3, article 313, 2013.
5. A. De Stefano and C. Carlomagno, "Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer, " World Journal of Gastroenterology, vol. 20, no. 29, pp. 9732-9743, 2014.
6. J. Mazieres, S. Peters, B. Lepage et al., "Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives, " Journal of Clinical Oncology, vol. 31, no. 16, pp. 1997-2003, 2013.
7. D. S. Ettinger, D. E. Wood, W. Akerley et al., NCCN Clinical Practice Guidelines in Oncology: Non-small Cell Lung Cancer, Version 4. 2014, National Comprehensive CancerNetwork, 2014.
8. A.-M. Tsimberidou, N. G. Iskander, D. S. Hong et al., "Personalized medicine in a phase I clinical trials program: The MD Anderson Cancer Center initiative, " Clinical Cancer Research, vol. 18, no. 22, pp. 6373-6383, 2012.
9. P. L. Bedard, A. M. Oza, M.-S. Tsao et al., "Princess Margaret Cancer Centre (PMCC) Integrated Molecular Profiling in Advanced Cancers Trial (IMPACT) using genotyping and targeted next-generation sequencing (NGS), " Journal of Clinical Oncology, vol. 31, supplement, abstract 11002, 2013.
10. R. Epelbaum, E. Shacham-Shmueli, R. Geva et al., "Molecular profiling (MP)-selected therapy for the treatment of patients with advanced pancreaticobiliary cancer (PBC), " Journal of Clinical Oncology, vol. 31, supplement 4, abstract 195, 2013.
11. G. S. Jameson, E. F. Petricoin, J. Sachdev et al., "A pilot study utilizingmulti-omicmolecular profiling to find potential targets and select individualized treatments forpatientswithpreviously treated metastatic breast cancer, " Breast Cancer Research and Treatment, vol. 147, no. 3, pp. 579-588, 2014.
12. A. Popovtzer, "Bio-marker driven tailored treatment for metastatic adenoid cystic carcinoma, " in Proceedings of the 8th International Conference on Head and Neck Cancer, Toronto, Canada, July 2012.
13. D. D. Von Hoff, J. J. Stephenson Jr., P. Rosen et al., "Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers, " Journal of ClinicalOncology, vol. 28, no. 33, pp. 4877-4883, 2010.
14. R. P. Harris, M. Helfand, S. H. Woolf et al., "Current methods of the US Preventive Services Task Force: A review of the process, " American Journal of Preventive Medicine, vol. 20, no. 3, supplement, pp. 21-35, 2001.
15. E. A. Eisenhauer, P. Therasse, J. Bogaerts et al., "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1. 1), " European Journal of Cancer, vol. 45, no. 2, pp. 228-247, 2009.
16. M. M. Oken, R. H. Creech, D. C. Tormey et al., "Toxicity and response criteria of the Eastern Cooperative Oncology Group, " American Journal of Clinical Oncology, vol. 5, pp. 649-655, 1982.
17. M. Buyse, E. Quinaux, A. Hendlisz, V. Golfinopoulos, C. Tournigand, and R. Mick, "Progression-free survival ratio as end point for phase II trials in advanced solid tumors, " Journal of Clinical Oncology, vol. 29, no. 15, pp. e451-e452, 2011.
18. A. Bonetti, M. Zaninelli, R. Leone et al., "Use of the ratio of time to progression following first-and second-line therapy to document the activity of the combination of oxaliplatin with 5-fluorouracil in the treatment of colorectal carcinoma, " Annals of Oncology, vol. 12, no. 2, pp. 187-191, 2001.
19. P. Comella, R. Casaretti, E. Crucitta et al., "Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i. v. bolus: A salvage regimen for colorectal cancer patients, " British Journal of Cancer, vol. 86, pp. 1871-1875, 2002.
20. D. B. Jackson, "Clinical and economic impact of the nonresponder phenomenon-implications for systems based discovery, " Drug Discovery Today, vol. 14, no. 7-8, pp. 380-385, 2009.
21. E. Bruera and S. Yennurajalingam, "Palliative care in advanced cancer patients: how and when?" Oncologist, vol. 17, no. 2, pp. 267-273, 2012.
22. M. Schwaederle, B. A. Parker, R. B. Schwab et al., "Molecular tumor board: The University of California-San Diego Moores Cancer Center experience, " Oncologist, vol. 19, no. 6, pp. 631-636, 2014.
23. C. Le Tourneau, M. Kamal, O. Trédan et al., "Designs and challenges for personalizedmedicine studies in oncology: focus on the SHIVAtrial, " Targeted Oncology, vol. 7, no. 4, pp. 253-265, 2012.
24. H. Blons, E. Rouleau, N. Charrier et al., "Performance and cost efficiency of KRAS mutation testing for metastatic colorectal cancer in routine diagnosis: The MOKAECM Study, a nationwide experience, " PLoS ONE, vol. 8, no. 7, Article ID e68945, 2013.
25. R. Rouzier, P. Pronzato, E. Chéreau, J. Carlson, B. Hunt, and W. J. Valentine, "Multigene assays andmolecularmarkers in breast cancer: systematic review of health economic analyses, " Breast Cancer Research and Treatment, vol. 139, no. 3, pp. 621-637, 2013.
26. C. B. Weldon, J. R. Trosman, W. J. Gradishar, A. B. Benson III, and J. C. Schink, "Barriers to the use of personalized medicine in breast cancer, " Journal of Oncology Practice, vol. 8, no. 4, pp. e24-e31, 2012.